AI Summary

Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy Advisers to the Food and Drug Administration (FDA) will soon hold a meeting about whether to ease restrictions on access to some research peptides, a group of drugs with a zealous following and thin evidence to support them. If restriction…

AI summaries can be wrong sometimes—always verify important details using the source article.